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S U M M A R Y
Objective: To evaluate the impact of the International Nosocomial Infection Control Consortium (INICC)
multidimensional infection control approach on central line-associated bloodstream infection (CLABSI)
rates in eight cities of India.
Methods: This was a prospective, before-and-after cohort study of 35 650 patients hospitalized in 16
adult intensive care units of 11 hospitals. During the baseline period, outcome surveillance of CLABSI was
performed, applying the deﬁnitions of the CDC/NHSN (US Centers for Disease Control and Prevention/
National Healthcare Safety Network). During the intervention, the INICC approach was implemented,
which included a bundle of interventions, education, outcome surveillance, process surveillance,
feedback on CLABSI rates and consequences, and performance feedback. Random effects Poisson
regression was used for clustering of CLABSI rates across time periods.
Results: During the baseline period, 9472 central line (CL)-days and 61 CLABSIs were recorded; during
the intervention period, 80 898 CL-days and 404 CLABSIs were recorded. The baseline rate was 6.4
CLABSIs per 1000 CL-days, which was reduced to 3.9 CLABSIs per 1000 CL-days in the second year and
maintained for 36 months of follow-up, accounting for a 53% CLABSI rate reduction (incidence rate ratio
0.47, 95% conﬁdence interval 0.31–0.70; p = 0.0001).
Conclusions: Implementing the six components of the INICC approach simultaneously was associated
with a signiﬁcant reduction in the CLABSI rate in India, which remained stable during 36 months of
follow-up.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Central line-associated bloodstream infections (CLABSIs) are
responsible for increased lengths of hospital stay and increased
attributable mortality in high-income countries1 and in limited-
resource countries,2 including India.3 CLABSIs are also responsible
for increased health care costs, as reported in studies from high-
income countries1 and from some limited-resource countries in
Latin America;2,4 however, no data on costs of CLABSIs are
available from India.
The incidence of CLABSI is many times underestimated in
limited-resource countries, as basic infection control programs are
not systematically implemented.5 Device-associated healthcare-
acquired infection (DA-HAI) rates in the intensive care units (ICUs)
of limited-resource countries are three to ﬁve times higher than in
high-income countries, as reported by the International Nosoco-
mial Infection Control Consortium (INICC) in pooled studies,5 and
particularly in India.3
In developing countries, the socioeconomic level of the country
has an impact on DA-HAI rates in the pediatric6 and neonatal7 ICU
settings. However, far too little attention has been paid to this, as
only two studies addressing this issue have been published. The
results of one of the studies showed that lower-middle-income
countries had higher CLABSI rates than upper-middle-income
countries in pediatric ICUs (12.2 vs. 5.5 per 1000 central line (CL)-
days).6 Similarly, in the other study, CLABSI rates were signiﬁcantly
higher in neonatal ICU patients from low-income countries than in
those from lower-middle-income countries or upper-middle-
income countries (37.0 vs. 11.9 (p < 0.02), and vs. 17.6
(p < 0.05) CLABSIs per 1000 catheter-days, respectively).7 Unfor-
tunately, no studies from developing countries that have analyzed
this issue in adult ICUs (AICUs) are available.
In developed countries, it has been demonstrated that
surveillance is fundamental to the prevention of CLABSIs, which
can be reduced by more than 30%.8 Implementing infection control
bundles, including the ﬁve interventions (1) hand hygiene, (2) skin
antisepsis with chlorhexidine, (3) maximal barriers, (4) insertion
into the subclavian vein, and (5) timely CL removal, has been
associated with a reduction in the incidence density of CLABSI in
developed countries.9
The present study was designed to determine the effect of a
multidimensional program for CLABSI prevention in 16 AICUs of
11 hospitals, in eight cities of India. Our program was imple-
mented from September 2004 to February 2012 and included
six simultaneous interventions: (1) practice bundle, (2) educa-
tion, (3) outcome surveillance, (4) process surveillance, (5)
feedback of CLABSI rates, and (6) performance feedback on
infection control practices. The design of the INICC multidimen-
sional approach follows the basic recommendations published in
the guidelines of the Society for Health Care Epidemiology of6.44
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Figure 1. Central line-associated bloodAmerica (SHEA) and the Infectious Diseases Society of America
(IDSA) in 2008.10
So far there has been no systematic research on the effect of
such an approach in India, the second most populous country in the
world, with a population of around 1 300 000 000 people. This
provided sufﬁcient ethical and theoretical justiﬁcation for
conducting this particular study, and through its publication,
increase and spread awareness of this public health burden in
India.11
2. Methods
2.1. Background on INICC
Founded in Argentina in 1998, the INICC was the ﬁrst
multinational research network established to control and reduce
HAIs at the international level through the analysis of data
collected on a voluntary basis by a pool of hospitals worldwide.12
The goals of the INICC include the development of a dynamic global
hospital network that applies systematic surveillance of HAIs with
standardized deﬁnitions and methodologies, the promotion of
evidence-based infection control practices, and the performance of
applied infection control research to reduce rates of HAIs, the
associated mortality, excess lengths of hospital stay, costs, and
bacterial resistance.13
2.2. Setting and study design
The study was conducted in 16 AICUs in 11 hospitals, all members
of the INICC, in eight cities of India. Each hospital had been actively
participating in the INICC surveillance program for a minimum of
6 months,withan infection control team (ICT)comprisedof infection
control professionals (ICPs) and a medical doctor with a formal
education and background in internal medicine, critical care,
infectious diseases, and/or hospital epidemiology.
This prospective, before-and-after study was performed over
two time-periods: the baseline period and the intervention period.
The institutional review board at each hospital approved the study
protocol (Figure 1).
2.3. Baseline period
The baseline period included only the performance of outcome
surveillance and process surveillance. The length of the baseline
period was 3 months for the following three reasons: (1) This is the
time needed to conduct the following activities at INICC
headquarters in Argentina on a monthly basis: receiving those
case report forms (CRF) completed at all participating ICUs from
India; conducting a validation process of ﬁlled CRFs; sending2.49
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queries; uploading and analyzing CRF data; producing monthly
reports containing charts and tables with the results of outcome
and process surveillance; sending monthly reports to each ICU;
presenting the monthly report to health care workers (HCWs)
at the participating ICUs at monthly infection control meetings,
with the aim of providing feedback on CLABSI rates and their
consequences and performance feedback to increase awareness
about CLABSIs and to improve compliance with infection control
practices.11 (2) The sample size of patients and number of months
of data collection during the baseline period are sufﬁcient
for comparison with the sample size of patients and number of
months of data collection during the intervention period. From a
statistical perspective, the issue is addressed by considering
the changes in rates over time. The relatively short baseline period
may have had an impact on the standard errors of our estimates.
However, we found that this did not bias the results, because there
were no systematic differences between the two groups. (3) Our
priority was to start the intervention as early as possible in order
to achieve the desired results—reducing the CLABSI and mortality
rates as soon as possible.
2.4. Intervention period
The intervention period was initiated after 3 months of
participation in the INICC program. This was a cohort study, and
for that reason, each ICU joined the INICC program at a different time.
Thus, by the day we analyzed the impact of the INICC intervention,
the ICUs had undergone different lengths of intervention. The
average length of the intervention period was 17.54 months
(standard deviation 8.9 months, range 5–36 months).
2.5. INICC multidimensional infection control approach
The INICC multidimensional infection control approach includ-
ed the following items: (1) bundle of infection control interven-
tions, (2) education, (3) outcome surveillance, (4) process
surveillance, (5) feedback of CLABSI rates, and (6) performance
feedback of infection control practices.
2.5.1. Components of the central line-care bundle for CLABSI
Components of the CL-care bundle for CLABSI were as follows:10
1. Perform hand hygiene before CL insertion or manipulation;14
2. Use sterile gauze or a transparent sterile dressing to cover the
insertion site;10
3. Maintain a good condition of the sterile dressing. Change the
gauze every 48 h and the transparent dressing every 7 days;10
4. Remove the CL as early as possible, when not necessary;10
5. Change the administration set every 96 h; unless used for fat,
nutrition, or blood precuts, and in these cases change every
24 h;10
6. Use a chlorhexidine-based antiseptic for skin preparation;10
7. Preferably use the subclavian vein;10
8. Use an all-inclusive catheter cart or kit;15
9. Use maximal sterile barrier precautions during CL insertion;10
10. Avoid using several times those vials meant to be used only
once;10
11. Disinfect line hubs, needleless connectors, and infection ports
before accessing the CL.10
Other effective interventions were discussed but not applied
because of budget limitations, namely the following ﬁve practices
were partially applied or not applied:
1. Use of a split septum instead of mechanical valves or a three-
way stopcock;102. Use of a chlorhexidine impregnated sponge at the insertion
site;10
3. Daily bath with chlorhexidine;10
4. Use of antimicrobial impregnated catheters;10
5. Use of closed collapsible ﬂexible containers instead of open
semi-rigid vented or glass vented IV containers.16
2.5.2. Education
Monthly sessions of education for CLABSI prevention were
provided by the ICP to the HCWs in charge of the insertion, care,
and maintenance of CLs, based on SHEA and IDSA guidelines.10,11
2.5.3. INICC surveillance methods
The INICC surveillance program included two components:
outcome surveillance (DA-HAI rates and their adverse effects,
including mortality rates) and process surveillance (adherence to
hand hygiene (HH) and other basic preventive infection control
practices).13
Investigators were required to complete outcome and process
surveillance forms in their ICUs, which were then sent for monthly
analysis to the INICC headquarters ofﬁce in Buenos Aires.
2.5.4. Outcome surveillance
Outcome surveillance included rates of CLABSI per 1000 CL-
days, use of invasive devices (CL, mechanical ventilator, and
urinary catheter), severity of illness score, underlying diseases, use
of antibiotics, culture taken, microorganism proﬁle, bacterial
resistance, length of stay, and mortality in the ICU.13
CLABSI deﬁnitions and surveillance methods were in accor-
dance with the deﬁnitions for HAI developed by the US Centers for
Disease Control and Prevention (CDC) for the National Healthcare
Safety Network (NHSN) program.17 Additionally, INICC methods
were adapted to the limited-resource setting of developing
countries, due to their different socioeconomic status.13 The ASIS
(Average Severity of Illness Score) was used instead of the APACHE
II score (Acute Physiology and Chronic Health Evaluation) due to
budget limitations of participating ICUs in this limited-resource
country. Thus, we used the ASIS score, as historically used by the
CDC National Nosocomial Infections Surveillance.18
2.5.5. Deﬁnitions
When CLABSI was suspected, the CL was removed aseptically
and the distal 5 cm of the catheter cut off and cultured using the
standardized semi-quantitative method.17,18 Concomitant blood
cultures were drawn percutaneously in most cases. At each
hospital, standard laboratory methods were used to identify
microorganisms, and standardized susceptibility testing was
performed.17,18 A laboratory conﬁrmed CLABSI was deﬁned in
the following case: A patient with a CL from whom a recognized
pathogen is isolated from one or more percutaneous blood cultures
after 48 h of catheterization; the pathogen cultured from the blood
is not related to an infection at another site; and the patient has one
or more of the following signs or symptoms: fever (38 8C), chills,
or hypotension. In the case of skin commensals being isolated
(diphtheroids, Bacillus spp, Propionibacterium spp, coagulase-
negative staphylococci, and micrococci), the organism had to have
been recovered from two or more separate blood cultures.17–19
2.5.6. Process surveillance
Process surveillance was designed to assess compliance with
easily measurable key infection control practices, such as
surveillance of compliance rates for HH practices and speciﬁc
measures for the prevention of CLABSI.13
Due to budget limitations, only ﬁve out of 11 components of the
bundle were monitored:
Table 1
Characteristics of the participating ICUs and hospitals (from September 2004 to
January 2011)
Data AICUs, n AICU patients, n
Type of ICU, n (%)
Cardiac surgical 1 (6%) 3024
Cardiac medical 1 (6%) 2348
Surgical 3 (19%) 5053
Medical 4 (25%) 5230
Adult step-down 1 (6%) 1353
Medical surgical 6 (38%) 17 743
All AICUs 16 (100%) 35 650
Type of hospital, n (%)
Private community 9 (82%) 28 682
Academic teaching 1 (9%) 2348
Public 1 (9%) 4620
All hospitals 11 35 650
ICU, intensive care unit; AICU, adult ICU.
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frequency with which HH was performed as indicated in HCW
infection control training. Observing ICPs were trained to record
HH opportunities and compliance on a form, during randomly
selected observation periods of 30 min to 1 h, 3 times a week. In
particular, the INICC direct observation comprised the ‘‘Five
Moments for Hand Hygiene’’ as recommended by the World
Health Organization (WHO). The ‘Five Moments’ included the
monitoring of the following moments: (1) before patient
contact, (2) before an aseptic task, (3) after body ﬂuid exposure
risk, (4) after patient contact, and (5) after contact with patient
surroundings.20 Although HCWs knew that hand hygiene
practices were regularly monitored, they were not informed
of the schedule for HH observations.
2. Data on compliance with CL care measures were recorded 5 days
a week on a form that evaluated if infection control procedures
were correctly carried out by the HCW. The ICP observing the
activity in the AICU completed a standardized form that
contained the following data: total number of inserted CLs for
each patient for the whole ICU; total number of dressings placed
to protect the puncture site, in order to evaluate the number of
patients with a sterile dressing.13
3. The ICP completed a standardized form that contained the total
number of dressings in correct condition and an evaluation of
whether the dressing was clean, dry, and correctly adhered to
the puncture site, so as to evaluate the number of dressings in
the correct condition.13
4. The ICP also completed a standardized form that contained the
total number of cases in which the dates in the administration
set were written, with the aim of measuring the number of
patients with the number of days of the administration set in
place, and evaluating if the set was replaced by or before 96 h.13
5. Finally, the ICP completed a standardized form including the
date of insertion and removal of each CL, to evaluate the number
of days the CL was inserted and the earliest possible removal of
the CL when not necessary.
2.5.7. Feedback on DA-HAI rates
Every month, the INICC research team at INICC headquarters in
Buenos Aires, prepared and sent to each ICT a ﬁnal report of the
results of outcome surveillance data sent by the investigators at
each hospital, i.e., monthly DA-HAI rates, length of stay, bacterial
proﬁle and resistance, and mortality.13
Feedback on DA-HAI rates was provided to HCWs working in
the AICU by communicating the patient outcomes. The resulting
rates were reviewed by the ICT at monthly meetings, where charts
were analyzed. Statistical graphs and visuals were displayed in
prominent locations inside the ICU to provide an overview of DA-
HAI rates. This infection control tool is important to increase
awareness of patient outcomes in the ICU and to enable ICT and ICU
staff to focus on the necessary issues and apply speciﬁc strategies
to improve high DA-HAI rates.
2.5.8. Performance feedback
Upon processing the hospital process surveillance data on a
monthly basis, the INICC research team at INICC headquarters in
Buenos Aires prepares and sends to each ICT a ﬁnal report of the
results of process surveillance rates, including compliance with HH
and care of CLs.13
Performance feedback is provided to HCWs working in the
AICU by communicating the assessment of practices routinely
performed by them. The resulting rates are reviewed by the ICT at
monthly meetings, where charts are analyzed; statistical graphs
and visuals are posted inside the ICU to provide an overview of
rates measuring compliance with infection control practices. This
infection control tool is key to enabling the ICT and ICU staff tofocus on the strategies necessary to improve low compliance
rates.
2.6. Statistical methods
Patient characteristics during the baseline and intervention
periods in each ICU were compared using Fisher’s exact test for
dichotomous variables and an unmatched Student’s t-test for
continuous variables. 95% Conﬁdence intervals (CI) were calculat-
ed using VCStat (Castiglia). Relative risk (RR) ratios with 95%
conﬁdence intervals (CI) were calculated for comparisons of rates
of CLABSI using Epi Info v. 6. p-Values of < 0.05 by two-sided tests
were considered signiﬁcant.
We conducted two types of analysis to evaluate the impact of
our intervention on CLABSI rates. First, we performed an analysis to
compare the data of the ﬁrst 3 months (baseline period) with the
remaining pooled months (intervention period), using the RR, 95%
CI, and p-value. Second, in order to analyze a progressive CLABSI
rate reduction, we used Poisson regression. We divided the data
into the ﬁrst 3 months (baseline period), followed by a 9-month
period (intervention period), and two annual follow-up periods for
the second and third years. We compared the CLABSI rates for each
follow-up period with the baseline CLABSI rate. For this compari-
son, we used the baseline data only of those hospitals that
contributed to the follow-up during that period (i.e. excluding from
the baseline those hospitals with long lengths of follow-up that
only contributed a shorter length of surveillance). We used random
effects Poisson regression to account for clustering of CLABSI rates
within hospitals across time periods. These models were estimated
using Stata 11.0. For this analysis we used the incidence rate ratio
(IRR), 95% CI, and p-value.
3. Results
During the whole study, a total of 35 650 patients were
hospitalized in 16 AICUs during 173 056 days, amounting to
90 370 CL-days. Participating hospitals were classiﬁed according
to the type of hospital and type of AICU. The ﬁrst ICUs to
participate were enrolled in September 2004, and the most
updated data included our analysis dates from February 2012
(Table 1).
Patient characteristics, such as thoracic surgery, immune
compromise, mechanical ventilator use, and ASIS, were similar
in the two periods (Table 2). However, the mean age of patients
was higher during the intervention period (Table 2).
In relation to compliance rates, during the baseline period, HH
compliance improved signiﬁcantly and the CL use ratio was
reduced. Compliance with other measures, such as date on
Table 2
Characteristics of patients, hand hygiene compliance, central line care compliance, central line use, and CLABSI rates in phase 1 (baseline period) and phase 2 (intervention
period)
Patient characteristics Phase 1—baseline Phase 2—intervention RR 95% CI p-Value
Study period by hospital in months, mean  SD (range) 3 17.54  8.9 (5–36) - - -
Number of patients 3747 31 903 - - -
Bed-days,a n 17 395 155 661
Number of CL days,b n 9472 80 898
CL duration, mean  SD 2.53  4.4 2.54  5.8 - - 0.9
Number of MV days,b n 4088 35 636
MV use,c mean 0.24 0.23 0.97 0.94–1.0 0.13
Age, years, mean  SD 55.0  18.0 56.3  18.0 - - 0.0001
ASIS score, mean  SD 2.62  1.14 2.6  1.1 - - 0.7
Male 2590 (69%) 20 602 (65%) 0.94 0.9–0.97 0.0013
Female 1156 (31%) 11 259 (35%) - - -
Thoracic surgery, n (%) 11 (1%) 91 (1%) 0.97 0.52–1.82 0.94
Immune compromise, n (%) 11 (1%) 142 (1%) 1.52 0.82–2.81 0.18
Hand hygiene compliance, n (%) 73% (1467/2013) 84% (17 914/21 327) 1.15 1.1–1.22 0.0001
Compliance with date on administration set % (n/n) 97% (4405/4532) 96% (39 581/41 247) 0.99 0.96–1.02 0.42
Compliance with placed dressing % (n/n) 99% (4493/4532) 98% (40 248/41 247) 0.98 0.95–1.02 0.313
Compliance with correct condition of dressing % (n/n) 94.4% (4277/4532) 92% (37 904/41 247) 0.97 0.94–1.01 0.1
CL use,c mean 0.54 0.52 0.95 0.93–0.97 0.0001
No. of CLABSI, n 61 404
CLABSI rate per 1000 CL-days (95% CI) 6.4 (4.9–8.3) 3.9 (3.5–4.3) 0.61 0.46–0.81 0.0007
ASIS, Average Severity of Illness Score; CI, conﬁdence interval; CL, central line; CLABSI, central line-associated bloodstream infection; MV, mechanical ventilation; RR, relative
risk; SD, standard deviation.
a Bed-days: the total number of days that patients are in the ICU during the selected time-period.
b CL-days: the total number of days of exposure to a central line for all of the patients in the selected population during the selected time-period; MV-days: the total
number of days of mechanical ventilation for all of the patients in the selected population during the selected time-period.
c CL and MV use ratios were calculated by dividing the total number of CL-days or MV-days by the total number of bed-days.
Table 3
CLABSI stratiﬁed by length of participation of each ICU in the INICC; Poisson regression analysis
Time since joining INICC Number of
ICUs
CL-days, n CLABSI, n Crude LCBI
rate/1000 CL-days
IRR accounting for
clustering by ICU
p-Value
1–3 months (baseline) 16 9472 61 6.44 (95% CI 4.9–8.3) 1.0 -
4–6 months 16 8814 23 2.61 (95% CI 1.7–3.9) 0.42 (95% CI 0.26–0.68) 0.0001
7–9 months 14 12 210 23 1.88 (95% CI 1.2–2.8) 0.31 (95% CI 0.19–0.51) 0.0001
10–12 months 13 8429 21 2.49 (95% CI 1.5–3.8) 0.30 (95% CI 0.18–50.2) 0.0001
13–18 months 15 18 220 64 3.51 (95% CI 2.7–4.5) 0.41 (95% CI 0.28–0.59) 0.0001
19–24 months 12 14 412 69 4.79 (95% CI 3.7–6.1) 0.48 (95% CI 0.34–0.70) 0.0001
Third year 9 18 813 78 4.15 (95% CI 3.3–5.2) 0.47 (95% CI 0.31–0.70) 0.0001
CI, conﬁdence interval; CL, central line; CLABSI, central line-associated bloodstream infection; ICU, intensive care unit; INICC, international nosocomial infection control
consortium; LCBI, laboratory-conﬁrmed bloodstream infection; IRR, incidence rate ratio.
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dressing, were high and similar in the two periods (Table 2).
During the baseline period, we recorded 9472 CL-days, for a CL
use mean of 0.54. There were 61 CLABSIs, for an overall baseline
rate of 6.4 CLABSIs per 1000 CL-days (Table 2). Merging all data
from the intervention period, during the implementation of the
multidimensional infection control program, we recorded 80 898Table 4
Microorganism related to CLABSI in AICUs in phase 1 (baseline period) and phase 2
(intervention period)
Microorganisms isolated Baseline, % (n) Intervention, % (n)
Klebsiella spp 32% (11) 25% (72)
Acinetobacter spp 18% (6) 10% (30)
Candida spp 12% (4) 15% (42)
Staphylococcus aureus 12% (4) 2% (7)
Enterococcus spp 6% (2) 4% (11)
Pseudomonas spp 6% (2) 16% (45)
Escherichia coli 3% (1) 7% (19)
Enterobacter spp 0% (0) 7% (20)
Flavobacterium spp 0% (0) 5% (15)
Coagulase-negative staphylococci 6% (2) 4% (11)
Stenotrophomonas spp 0% (0) 2% (6)
Other microorganisms 6% (2) 3% (9)
Total 100% (34) 100% (287)
AICU, adult intensive care unit; CLABSI, central line-associated bloodstream
infection.CL-days, for a CL use mean of 0.52. There were 404 CLABSIs for an
incidence density of 3.9 per 1000 CL-days. These results showed an
overall reduction in the CLABSI rate from baseline of 39% (from 6.4
to 3.9 CLABSIs per 1000 CL-days; RR 0.61, 95% CI 0.5–0.8;
p = 0.0001) (Table 2).
On the other hand, using Poisson regression, we found a
progressive CLABSI reduction. The baseline CLABSI rate (during
ﬁrst 3 months of the study) was 6.4 CLABSIs per 1000 CL-days,
which reduced progressively during the intervention period to 4.1
CLABSIs per 1000 CL-days in the third year, amounting to a 53%
CLABSI rate reduction (IRR 0.47, 95% CI 0.31–0.70; p = 0.0001)
(Table 3).
The microorganism proﬁle is shown in Table 4. The predomi-
nant microorganism in both phases was Klebsiella spp.
4. Discussion
This study set out with the aim of assessing the effect of a
multidimensional infection control approach in the ICU setting in
India, a limited-resource country. If compared with rates in
developed countries, the baseline rate of CLABSI found in this study
(9.0 per 1000 CL-days) is around eight-fold higher than in the USA
(1.1 per 1000 CL-days; as determined by the CDC/NSHN21) and
higher than the CLABSI rate determined by KISS (1.4 per 1000 CL-
days).22
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countries, our CLABSI baseline rate is similar to those reported in
the third and fourth international INICC reports published in 2010
(7.6 CLABSIs per 1000 CL-days)23 and 2012 (6.8 CLABSIs per 1000
CL-days).24
Within the scope of other studies addressing the burden of
CLABSIs in India, the CLABSI rate of our study is similar to the rate
found in another study conducted in India, showing 7.92 CLABSIs
per 1000 CL-days.3
In previous studies performed by INICC member hospitals, it
was shown that the implementation of a six-component multidi-
mensional approach for CLABSI resulted in signiﬁcant reductions in
the rates of CLABSI in Argentina (46.63 vs. 11.10 CLABSIs per 1000
CL-days),25 Mexico (46.3 vs. 19.5 CLABSIs per 1000 CL-days),26 in
AICUs (14.5 vs. 9.7 CLABSIs per 1000 CL-days),27 and in pediatric
ICUs (10.7 vs. 5.2 CLABSIs per 1000 CL-days).28
In our study, patient characteristics, such as thoracic surgery,
immune compromise, mechanical ventilator use, and the ASIS
severity of illness score, showed similar patient intrinsic risk in
both study periods. By contrast, the mean age of patients was
higher during the intervention period, meaning that the patient
intrinsic risks were higher in the intervention period. During the
implementation of the INICC multidimensional approach, we
found an improvement in process surveillance rates, with higher
HH compliance, and the CL use ratio was reduced. Compliance with
other measures, such as the date on the administration set, placed
dressing and correct condition of dressing, were high and similar in
both phases. During the study period, the high CLABSI rate at
baseline was reduced from 9.0 to 4.1 per 1000 CL-days, showing a
53% CLABSI rate reduction and evidencing the effectiveness of the
applied multidimensional approach.
Comparing our study with an earlier bundle study,9 we found
some differences. First, the previously published bundle included
ﬁve elements, whereas we included 11. Second, compliance was
not measured for any of the bundle components, whereas we
checked compliance with ﬁve bundle components. Third, char-
acteristics of patients during the baseline and intervention periods
were not collected or analyzed so as to check and compare
individual features, whereas we did, and found that our patients
were statistically similar in the two periods. Fourth, the follow-up
period was 18 months, whereas we included a 36-month follow-up
period. Fifth, the intervention included only a bundle and a check
list, whereas our study included the above-mentioned six
simultaneous interventions. Finally, microorganisms responsible
for the CLABSIs were not provided, whereas in our study we
included the CLABSI microorganism proﬁle for both the baseline
and intervention periods. The most important differences were
measurements of the population features and compliance with
bundle elements, which allowed us to analyze the real impact of
our intervention by excluding confounders associated with patient
characteristics and infection control practices.
Regarding the microorganism proﬁle, we identiﬁed a predomi-
nance of Klebsiella spp during both periods; this is similar to other
studies conducted in limited-resource countries.23
This study had limitations. The main limitation of this study is
that our ﬁndings cannot be generalized to all ICU patients in India.
However, in this study it was proved that a multidimensional
approach is fundamental to reduce the incidence of CLABSIs in the
ICU setting. Second, the use of a 3-month baseline period, which is
short, may have led to an overestimation of the effect of the
intervention. Nevertheless, the sample size was sufﬁcient during
the baseline period and the conﬁdence intervals for the baseline
rate were narrow. Third, there may be signiﬁcant variation in the
level of quality control in the laboratories that support each
individual hospital and we could not quantify in detail all the
interventions included in our multidimensional approach, such aseducation. Fourth, there might have been some ‘Hawthorne effect’
upon our study results; however, after years of continuous study
intervention with regular monitoring, the potential effect is
certainly diluted, as behavior is gradually internalized as a
permanent social norm. In addition, due to the fact that our study
design applies observational methods on HCW practice behaviors,
evidence may be less solid or have less corroborative value than in
other study designs. Finally, because of budget limitations, we
were not able to quantify compliance with some of the
components of our bundle. Thus we could not evaluate their
individual implications or other contextual factors related to the
ICU or hospitals individually. Nevertheless, our main goal was to
reduce the high baseline CLABSI rates found in ICUs and the
individual evaluation would have required more allocation of time,
contributing to unnecessary harm for ICU patients.
In conclusion, this is the ﬁrst multicenter study to report a
substantial reduction in CLABSI rates in the ICU setting in India.
Although some patient intrinsic risks were higher during the
intervention period, the implementation of our multidimensional
approach resulted in signiﬁcant reductions in the CLABSI incidence
rate. These systematically collected data serve as guidance for
strategies to improve patient care practices, as demonstrated in
several studies conducted in limited-resource countries.26,27 These
preventive strategies, proven effective in the INICC ICUs of India,
can promote a wider acceptance of infection control programs in
hospitals, leading to signiﬁcant CLABSI reductions worldwide.
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